Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DJ5B | ISIN: IE00BDGMC594 | Ticker-Symbol: AWK
Frankfurt
27.06.25 | 15:29
7,800 Euro
-1,27 % -0,100
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
AVADEL PHARMACEUTICALS PLC Chart 1 Jahr
5-Tage-Chart
AVADEL PHARMACEUTICALS PLC 5-Tage-Chart
RealtimeGeldBriefZeit
7,8507,90017:43
7,8507,90017:40

Aktuelle News zur AVADEL PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.06.Avadel Pharmaceuticals plc: Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)46DUBLIN, June 16, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee...
► Artikel lesen
05.06.Avadel Pharmaceuticals auf Jefferies-Konferenz: Strategisches Wachstum und Herausforderungen1
05.06.Avadel gets FDA's Orphan Drug status for sleep disorder treatment3
05.06.Avadel Pharma Says FDA Grants Orphan Drug Designation For LUMRYZ To Treat Idiopathic Hypersomnia1
05.06.FDA grants orphan drug status to Avadel's IH treatment3
AVADEL PHARMACEUTICALS Aktie jetzt für 0€ handeln
05.06.Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia74DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM...
► Artikel lesen
05.06.AVADEL PHARMACEUTICALS PLC - 8-K, Current Report-
13.05.Avadel appoints new COO to boost narcolepsy drug growth3
13.05.Avadel Pharmaceuticals appoints Susan Rodriguez as COO2
13.05.AVADEL PHARMACEUTICALS PLC - 8-K, Current Report1
13.05.Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer167DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 - Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced...
► Artikel lesen
08.05.Avadel Pharmaceuticals plc: Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)89DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee...
► Artikel lesen
07.05.AVADEL PHARMACEUTICALS PLC - 10-Q, Quarterly Report-
07.05.Avadel Pharmaceuticals GAAP EPS of -$0.051
07.05.Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance230-- Generated $52.5 million in net revenue from sales of LUMRYZ, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since...
► Artikel lesen
06.05.AVADEL PHARMACEUTICALS PLC - 8-K, Current Report-
06.05.Avadel wins appeal to expand LUMRYZ trials beyond narcolepsy3
06.05.Avadel gewinnt Berufung zur Ausweitung von LUMRYZ-Studien über Narkolepsie hinaus1
06.05.Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction109- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ for...
► Artikel lesen
06.05.Earnings Outlook For Avadel Pharmaceuticals1
Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1